| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
CDKI-73 manufacturers
- CDKI-73
-
- $146.00
-
2026-07-15
- CAS:1421693-22-2
- Purity: 98.11%
- Supply Ability: 10g
- CDKI-73
-
- $146.00
-
2026-07-15
- CAS:1421693-22-2
- Purity: 98.11%
- Supply Ability: 10g
|
| | CDKI-73 Basic information |
| Product Name: | CDKI-73 | | Synonyms: | CDKI-73;CS-2259;CDKI-73
(CDKI73);Benzenesulfonamide, 3-[[5-fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-;asnuciclib;toxicity,Inhibitor,low,AML,Acute,LS 007,myeloid,LS007,leukemia,CLL,Apoptosis,LS-007,endosome,Cyclin dependent kinase,CDKI73,CDKI-73,CDKI 73,inhibit,CDK;3-((5-Fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)benzenesulfonamide;3-[[5-fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-benzenesulfonamide | | CAS: | 1421693-22-2 | | MF: | C15H15FN6O2S2 | | MW: | 394.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1421693-22-2.mol |  |
| | CDKI-73 Chemical Properties |
| Boiling point | 642.9±65.0 °C(Predicted) | | density | 1.524±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:52.0(Max Conc. mg/mL);131.83(Max Conc. mM) | | form | Solid | | pka | 10.06±0.60(Predicted) | | color | Light yellow to yellow |
| | CDKI-73 Usage And Synthesis |
| Uses | 3-[[5-Fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]benzenesulfonamide is a potent CDK inhibitor. A highly efficacious CDK9 inhibitor against acute myeloid leukemia. | | in vivo | Asnuciclib (25, 50, 100 mg/kg) markedly decreases tumor growth in a dose-dependent manner and results in a prolongation of animal life span (P < 0.001) without causing body weight loss and other overt toxicities.[3].
| Animal Model: | MV4-11 tumor bearing mice[3]. | | Dosage: | 25 mg/kg. | | Administration: | Orally once everyday for 33 days. | | Result: | Caused a remarkable delay in tumor growth compared to vehicle-treated mice, as reflected in a percentage for the mean tumor volume in treated to control mice of 43% at day 31. |
| Animal Model: | Balb/C mice aged 6-8 weeks[3]. | | Dosage: | 2 mg/kg (IV), 10, 20 and 40 mg/kg (PO). (Pharmacokinetic Analysis.) | | Administration: | IV and PO, single dose. | | Result: | The Cmax increased from 1.29 to 3.66 μM at a mean time of 1 h and the area under the curve (AUC) of CDKI-73 increased from 3.51 to 12.8 μM.h when the oral dose was escalated from 10 to 40 mg/kg.
CDKI-73 was eliminated from plasma with a mean terminal half-life (T1/2) of 2 h. Its oral
bioavailability (F) ranged from 54 to 85% across the three doses.
|
| | IC 50 | CDK2: 3.27 nM (IC50); CDK9: 5.78 nM (IC50); CDK1: 8.17 nM (IC50); CDK4: 8.18 nM (IC50); CDK6: 37.68 nM (IC50); CDK7: 134.26 nM (IC50); CDK1: 4 nM (Ki); CDK2: 3 nM (Ki); CDK9: 4 nM (Ki); CDK7: 91 nM (Ki) |
| | CDKI-73 Preparation Products And Raw materials |
|